Ulisse Biomed S.p.A. (BIT:UBM)

Market Cap	21.15M
Revenue (ttm)	767.93K
Net Income (ttm)	-5.94M
Shares Out	24.48M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,000
Average Volume	145,700
Open	0.8540
Previous Close	0.8640
Day's Range	0.8240 - 0.8540
52-Week Range	0.6800 - 1.2700
Beta	0.70
RSI	61.02
Earnings Date	Sep 26, 2025

About Allakos

Ulisse Biomed S.p.A., a healthcare biotech company, develops, produces, and markets vitro diagnostic medical devices in Italy. The company through its Sagitta platform offers various tests, such as Ladymed/HPV Selfy for the detection of human papillomavirus (HPV); CoronaMelt, a diagnostic test for Sars- CoV-2; CoronaMelt Var, a diagnostic assay for the detection and genotyping of Sars-CoV-2 variants; and UlisseFaster, a reagent for the pre-treatment of biological samples. It provides various tests and reagents for sexually transmitted diseases ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 22
• Stock Exchange: Borsa Italiana
• Ticker Symbol: UBM

Financial Performance

In 2024, Ulisse Biomed's revenue was 767,929, an increase of 1059.87% compared to the previous year's 66,208. Losses were -5.94 million, 23.8% more than in 2023.